il-17f

IL-17 modulator 4 is a prodrug of IL-17 modulator 1, which is an efficacious modulator of IL-17.

IL-17 modulator 3 (US20200247785A1) is a chemical compound that acts as an IL-17 modulator. It has potential applications in researching inflammation, cancer, and autoimmune diseases.

F(N-Me)GA(N-Me)IL is a bioactive peptide derived from a partial IAPP sequence that contains double N-methylations. These modifications prevent the peptide from forming β-sheet structures and exhibiting amyloidogenicity or cytotoxicity. Additionally, the derivatives can interact with native sequences to inhibit amyloid formation.

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

IL-17 modulator 5 is a IL-17 inhibitor, with an IC 50 of 1 nM .

F-17 is a promising virulence factor inhibitor, displaying substantial inhibitory effects on biofilm formation, elastase activity, pyocyanin production, and swarming motility. Additionally, F-17 exhibits a strong binding affinity towards LasR and PqsR. Notably, F-17 does not exhibit any discernible cytotoxicity [1].

(R)-IL-17 modulator 4, the R-configured form of IL-17 modulator 4, is a prodrug of IL-17 modulator 1, which is a potent, orally active IL-17 modulator.

IL-17 modulator 4 sulfate is a prodrug of IL-17 modulator 1, which is an orally active and highly efficacious IL-17 modulator.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders[1].

Androgen receptor-IN-5 is a potent inhibitor of the androgen receptor with anticancer properties. It additionally suppresses the synthesis of IL-17A, IL-17F, and INF-γ.

Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody combining monovalent camelid-derived nanobodies targeting human interleukin (IL)-17A and IL-17F with human serum albumin VHHs, presenting it as a promising candidate for investigating plaque-type psoriasis treatments [1] [2].

Afasevikumab (RG 7624; RO 5553110; NI-1401), a fully human monoclonal IgG1κ antibody, neutralizes both IL-17A and IL-17F, exhibiting anti-inflammatory activities [1].

TMP778 is an effective and selective RORγt inverse agonist (IC50: 7 nM in FRET assay).

Bimekizumab (Anti-Human IL17A IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, which promote osteogenic differentiation in human periosteum-derived cells (hPDC), and consequently inhibits inflammation-driven osteogenic differentiation [1].